2022 Angiotensin GRC/GRS

项目摘要 肾素血管紧张素醛固酮系统（RAAS）是心血管（CV）功能、体液免疫和心血管疾病的关键调节因子。 电解质平衡和体内平衡，并且它影响许多系统，包括肾、神经内分泌和 免疫系统RAAS的扰动触发了一系列事件，包括血管活性物质的产生。 介质，氧化应激，炎症反应和组织重塑，从而有助于终末器官 病理学和疾病。在2022年的GRC on Ang中，我们将讨论最新的前沿发现， 该领域，并分享对CV系统以外新兴领域的见解，例如RAAS在以下方面的作用： 脂肪生物学、骨髓调节、肝功能、神经认知和免疫反应。的 会议将集中讨论RAAS从发现科学到临床影响的最新进展。一大亮点 2022年是ACE 2发现22周年。ACE 2是一种多功能蛋白质， 仅通过分别从Ang II和Ang I产生Ang-（1-7）和Ang-（1-9）来保护CV，但它也是， 作为SARS-CoV-2的受体，SARS-CoV-2是目前世界范围内的病原体， 2019冠状病毒病疫情。ACE 2作为RAAS保护臂中的关键酶之谜将是一个新的挑战。 highlight. ACE 2作为COVID-19中的主要介质和潜在治疗靶点的作用将被讨论 沿着关于COVID-19感染进展和人群长期结局的争议 用ACE抑制剂和/或血管紧张素受体阻滞剂治疗。2022年GRC on Ang将进一步展示 新的主题，包括性别差异的调节和变化的RAAS在生命过程中（胎儿 编程，肾脏发育和衰老）将进一步解决。与精准医疗相一致， 作为临床医学的下一个前沿领域，会议还将突出药物基因组学的新进展， 蛋白质组学和人类疾病中RAAS的代谢组学。在GRC之前，我们将有2022年 戈登研究研讨会（GRS），研究生，博士后研究员，早期职业的特殊论坛 研究人员和其他年轻科学家提出和交流新的数据和尖端的想法。2022年 GRS将专注于RAAS研究的最新进展，包括经典范式之外的新功能 从这一系统的受体，并提供受训人员与现有的工具，以帮助加强了解 他们的研究，并涵盖了广泛的主题，包括免疫系统，性别差异和衰老。 此外，导师会议将解决学术界和工业界之间的相互作用，并讨论 将科学发现转化为临床的方法以及如何优化影响。目标一致 与NHLBI、NIDDK和NIAID任务和倡议一起，将涵盖的科学主题如下 与这些机构有直接关系。NIH申请的资金将有助于吸引年轻的研究人员和受训人员， 包括来自代表性不足、机会有限的群体，与国家和国际顶级专家联合 在RAAS中，研究人员、临床医生、年轻的研究人员和受训人员之间建立网络。

PROJECT SUMMARY The renin angiotensin aldosterone system (RAAS) is a key regulator of cardiovascular (CV) function, fluid electrolyte balance, and homeostasis, and it influences many systems including the renal, neuroendocrine, and immune systems. Perturbations of the RAAS trigger a cascade of events, including generation of vasoactive mediators, oxidative stress, inflammatory responses, and tissue remodeling, thus contributing to end-organ pathology and disease. In the 2022 GRC on Ang, we will discuss the most recent, cutting-edge discoveries in the field and share insights on emerging new areas beyond the CV system such as the role of the RAAS in adipose biology, bone marrow regulation, liver function, neurocognition, and immune responses. The conference will focus on the latest advances of the RAAS from discovery science to clinical impact. A highlight in 2022 will be the celebration of 22 years of the discovery of ACE2. ACE2 is a multifunctional protein, that not only is CV protective by generating Ang-(1-7) and Ang-(1-9) from Ang II and Ang I respectively, but it is also, tissue injurious by acting as the receptor for the SARS-CoV-2, the etiologic agent of the current worldwide COVID-19 pandemic. The enigmas of ACE2 as a key enzyme in the protective arm of the RAAS will be a highlight. The role of ACE2 as a major mediator and potential therapeutic target in COVID-19 will be debated along with the controversies on the progression of COVID-19 infection and long-term outcomes in populations treated with ACE inhibitors and/or angiotensin receptor blockers. The 2022 GRC on Ang will further feature novel topics including sex-differences in the regulation and changes of the RAAS during the life course (fetal programming, kidney development, and aging) will be further addressed. In line with precision medicine being the next frontier in clinical medicine, the meeting will also highlight new advances in the pharmacogenomics, proteomics, and metabolomics of the RAAS in human diseases. Preceding the GRC, we will have the 2022 Gordon Research Seminar (GRS), a special forum for graduate students, postdoctoral fellows, early career researchers and other junior scientists to present and exchange new data and cutting-edge ideas. The 2022 GRS will focus on recent advances in RAAS studies beyond the classical paradigms, including new functions of receptors from this system and providing trainees with an enhanced understanding of current tools to aid their research, and cover a wide range of topics including the immune system, sex differences and aging. Additionally, the mentorship sessions will address the interplay between academia and industry and discuss approaches to translate scientific discoveries to the clinic and how to optimize impact. The aims are aligned with the NHLBI, NIDDK and NIAID missions and initiative and the scientific themes that will be covered are of direct relevance to these institutes. NIH funds requested will help attract young investigators and trainees, including from underrepresented groups with limited opportunities to joint top national and international experts in the RAAS for networking among researchers, clinicians, young investigators and trainees.